Affimed(AFMD) - 2023 Q1 - Quarterly Report
Affimed(AFMD)2023-03-22 16:00Exhibit 99.1 PRESS RELEASE Affimed Reports 2022 Financial Results and Operational Progress Heidelberg, Germany, March 23, 2023 – Affimed N.V. (Nasdaq: AFMD) ("Affimed" or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the year ended December 31, 2022, and provided an update on clinical and corporate progress. "During 2022, we presented data across our pipeline that show our innate cell enga ...